• AIBP-LRP2–HDL Axis Limits CXCR4+ Capillary Expansion in Isch

  2026-05-20

  This study elucidates a novel regulatory pathway in which AIBP and LRP2 mediate endothelial HDL uptake to suppress CXCR4+ stemlike capillary endothelial cell expansion, thereby restricting collateral circulation in ischemic disease. These findings clarify the two-phase process of vascular remodeling and highlight new targets for therapeutic revascularization.

• Anagliptin (SK-0403): Mechanistic Leverage in Vascular Diabe

  2026-05-20

  This article explores the dual mechanistic action of Anagliptin (SK-0403) as a DPP-4 inhibitor with direct vasorelaxant effects via Kv channels and SERCA pump activation, offering strategic guidance for translational researchers targeting diabetes and cardiovascular comorbidities.

• Sulfo-Cy3 NHS Ester: Advanced Probe Engineering for Protein

  2026-05-19

  Explore the scientific principles and unique applications of Sulfo-Cy3 NHS Ester, a hydrophilic fluorescent dye engineered for robust protein labeling. This article delivers an in-depth analysis, bridging latest vascular biology research with advanced assay design.

• Tetrahydromagnolol: Redefining CB2 Agonist Use in Metastatic

  2026-05-19

  Explore how tetrahydromagnolol, a potent peripheral CB2 receptor agonist, is transforming advanced cannabinoid receptor research. This article uniquely details its mechanistic advantages, protocol parameters, and specific value in metastatic GPCR signaling models.

• Lipid Scrambling in Ferroptosis: TMEM16F as a Tumor Immune G

  2026-05-18

  Yang et al. uncover TMEM16F-mediated lipid scrambling as a critical suppressor of ferroptosis, revealing how its disruption triggers tumor cell death and enhances immune rejection. This mechanistic insight reframes the plasma membrane as a key site of regulation in programmed necrosis, with implications for cancer therapy and immune modulation.

• Troglitazone in Tumor Microenvironment: Beyond PPARγ Agonism

  2026-05-18

  Explore how Troglitazone, a PPARγ agonist, uniquely advances research into TAM-targeted anti-tumor strategies and metabolic modulation. This article provides original, in-depth analysis of recent breakthroughs and their impact on experimental design in oncology.

• A20 Dampens Oxidized Self-DNA-Driven Inflammation in AKI Mod

  2026-05-17

  This study demonstrates that the ubiquitin-editing enzyme A20 mitigates acute kidney injury (AKI) by disrupting NEK7-NLRP3 inflammasome interactions in response to oxidized self-DNA. The findings reveal a new regulatory mechanism for sterile inflammation in AKI and present A20 and its peptide derivative as promising therapeutic modulators.

• Anagliptin-Induced Vasorelaxation: Roles of Kv Channels and

  2026-05-16

  This study demonstrates that Anagliptin (SK-0403) induces vasorelaxation in rabbit aortic smooth muscle by specifically activating voltage-dependent K+ (Kv) channels and the SERCA pump, without involving endothelium or classical cyclic nucleotide pathways. These findings expand mechanistic understanding of DPP-4 inhibitors in vascular pharmacology and suggest new research directions for diabetes–cardiovascular comorbidity.

• BIBR 1532: Applied Protocols and Troubleshooting in Telomera

  2026-05-15

  BIBR 1532 stands out as a selective telomerase inhibitor for dissecting cancer cell proliferation and apoptosis. This article demystifies its application in telomerase activity assays, highlights cutting-edge workflows, and delivers actionable troubleshooting strategies for molecular oncology research.

• Simvastatin (Zocor): Mechanistic Insights and Translational

  2026-05-15

  This thought-leadership article provides a mechanistic deep dive into Simvastatin (Zocor), unraveling its dual roles as a cholesterol-lowering agent and anti-cancer modulator. We highlight recent biophysical findings on lipid bilayer interactions, synthesize workflow best practices, and offer strategic guidance for translational researchers aiming to leverage Simvastatin’s pleiotropic effects in cardiovascular and oncology research. This analysis is grounded in cutting-edge literature and positions APExBIO’s Simvastatin (Zocor) as a cornerstone for robust, reproducible experimentation.

• Hepatic Cellular Interactions of PEGylated Iron Oxide Nanopa

  2026-05-14

  This study elucidates how size and PEG chain length of iron oxide nanoparticles dictate their uptake by distinct liver cell subtypes. By combining in vivo SPECT/CT imaging with primary cell assays, the authors reveal surprising cellular uptake hierarchies, informing rational nanomedicine design for reduced hepatic accumulation.

• SARS-CoV-2 N Protein Subverts GADD34-Driven Innate Immunity

  2026-05-14

  Liu et al. uncover a novel immune evasion mechanism in which the SARS-CoV-2 nucleocapsid protein sequesters GADD34 mRNA within atypical stress granule-like foci, thereby disrupting IRF3-mediated interferon responses. This mechanistic insight enhances our understanding of coronavirus pathogenesis and identifies new angles for antiviral research.

• Berberine Hydrochloride (SKU N1368): Reliable Cell Assay Sol

  2026-05-13

  This article addresses persistent laboratory challenges in cell viability and metabolic disease research, demonstrating how Berberine Hydrochloride (SKU N1368) from APExBIO delivers reproducible, data-backed results. Scenario-driven Q&A blocks guide biomedical researchers through evidence-based protocol design, troubleshooting, and product selection, with actionable insights for workflow optimization.

• Applied Insights: Bestatin (Ubenimex) in Cancer & MDR Assays

  2026-05-13

  Bestatin (Ubenimex) empowers precise inhibition of aminopeptidases, enabling robust multidrug resistance (MDR) and apoptosis assay workflows. This article demystifies experimental protocols, comparative advantages, and troubleshooting strategies for leveraging APExBIO’s Bestatin in translational research.

• GPC3-HSP70 mRNA Nanovaccine and PD-L1 Blockade in HCC Immuni

  2026-05-12

  This study introduces a novel mRNA nanovaccine encoding GPC3 CTL epitopes fused with HSP70, designed to enhance antigen-specific T-cell responses against hepatocellular carcinoma (HCC). By combining this nanovaccine with anti-PD-L1 therapy, the research demonstrates synergistic antitumor immunity, offering a promising strategy for advanced HCC treatment.

14775 records 1/985 page Next 12345 下5页 Last page